‘Doctrine of the Mean’: how the US lost a 2-decade race to China in brain implants

Shanghai-based Neuracle Medical Technology has achieved a landmark first in the brain-computer interface (BCI) field. The company's Neural Electronic Opportunity (Neo) implant has received commercial-use approval from China’s National Medical Products Administration, making it the world's first invasive BCI device available outside of clinical trials. This approval ends a global decades-long period where such technology was confined to research settings, signaling a major shift toward practical, commercial application.

The development pivots on a key design choice. Neuracle's team adopted a 'semi-invasive' approach, which the article frames as aligning with a Confucian 'doctrine of the mean' philosophy. This strategy seeks a middle path between the extremes of fully non-invasive BCIs (which are safer but less precise) and fully invasive ones (which offer high precision but carry greater surgical risks). By balancing these trade-offs, Neuracle has navigated a critical hurdle that has stalled other developers.

This commercial milestone represents a significant shift in the global BCI race. For over two decades, the United States, through companies like Neuralink and academic research, has been perceived as the leader in pursuing high-risk, high-reward breakthroughs. Neuracle's approval demonstrates that China has now crossed the commercial finish line first, moving a transformative neurotechnology from the lab to the clinic ahead of its Western competitors. The event underscores the intensifying geopolitical and technological competition in a field poised to revolutionize medicine and human-machine interaction.